News|Articles|October 2, 2026

AAOpt 2026: Demodex tied to worse MGD as dry eye questionnaires miss blepharitis

Author(s)Matt Hoffman
Fact checked by: Cheney Gazzam Baltz

Dry eye questionnaires capture only 22.4% of Demodex blepharitis symptoms, and a 22-study review links Demodex infestation to worse meibomian gland function.

Standard dry eye questionnaires capture only 22.4% of Demodex blepharitis symptoms, according to a targeted literature review presented at the American Academy of Optometry’s annual meeting, Academy 2026 Anaheim, held in California.1 A separate systematic review that was presented linked Demodex infestation to worse meibomian gland structure and function across 22 studies.2 An additional poster showed that neither perfluorohexyloctane (PFHO; Miebo; Bausch + Lomb) nor Systane Pro artificial tears (Alcon) clearly changed meibomian gland scores after 1 month.3

All the presentations bear directly on the lid margin workup in patients with meibomian gland dysfunction (MGD). Authors of the 2 reviews called on clinicians to evaluate Demodex directly rather than rely on symptom scores.1,2

Why do dry eye questionnaires miss Demodex blepharitis?

FREQUENTLY ASKED QUESTIONS

Can dry eye questionnaires screen for Demodex blepharitis?
No existing questionnaire is specific to Demodex blepharitis, and 6 widely used dry eye tools captured only 22.4% of its symptoms in a targeted literature review.
How is Demodex infestation linked to meibomian gland dysfunction (MGD)?
A systematic review of 22 studies found that patients with Demodex had worse meibum quality, more gland dropout, and shorter tear breakup time than patients without infestation.
What should optometrists know about Demodex in patients with MGD?
Both reviews support direct lid margin and lash evaluation in patients with MGD rather than relying on symptom questionnaires to identify Demodex.

Walter Whitley, OD, MBA, FAAO, and colleagues paired a targeted literature review with social media listening—monitoring patient posts on platforms such as Reddit and TikTok—to develop a patient-centered conceptual model of Demodex blepharitis.1 They identified 23 symptoms, most commonly watery eyes, itching, burning or stinging, redness, dryness, foreign body sensation, eyelash loss, and crusting. The team then screened 63 ocular patient-reported outcome measures, none specific to Demodex blepharitis.

Six dry eye instruments advanced to concept mapping, including the Dry Eye Questionnaire 5-item, the Ocular Surface Disease Index (OSDI), and the Standardized Patient Evaluation of Eye Dryness.1 On average, 72.8% of symptoms in these tools were relevant to Demodex blepharitis. Although the instruments captured only 22.4% of Demodex blepharitis symptoms, the authors concluded that this reflects poor content validity and may contribute to missed or incorrect diagnoses.

Demodex infestation and meibomian gland dysfunction outcomes

Bridgitte Shen Lee, OD, FAAO, and colleagues searched PubMed and Embase through January 6, 2026, for studies reporting MGD outcomes stratified by Demodex status, excluding interventional studies.2 One investigator extracted data, and a second verified it independently. Across 22 included studies, MGD prevalence ranged from 44% to 99% in patients with Demodex infestation, whereas Demodex prevalence ranged from 45% to 89% in patients with MGD.

Compared with patients without infestation, patients with Demodex had worse gland expressibility in 3 of 6 studies, poorer meibum quality in 6 of 8, and greater gland dropout and atrophy in 5 of 7. Lid margin abnormality scores were higher in 3 of 4 studies. Tear breakup time (TBUT) was shorter in all 4 studies reporting it, and corneal fluorescein staining was higher in both studies reporting it.2

Perfluorohexyloctane vs Systane Pro for meibomian gland function

In a randomized, double-masked, multisite trial, Andrew Pucker, OD, PhD, and colleagues compared PFHO with Systane Pro, each dosed 4 times daily for 1 month.3 Eligible adults had OSDI scores of 23 to 50, TBUT of 5 seconds or less, and Schirmer I scores of at least 5 mm in both eyes, selecting for evaporative dry eye. Investigators graded the central 8 upper and central 5 lower eyelid glands on a novel Meibomian Gland Composite Score, with lower scores indicating better function.

Right-eye TBUT rose from 3.65 to 5.33 seconds in the PFHO group (n = 86) and from 3.66 to 5.02 seconds in the Systane Pro group (n = 68). The authors reported numerical improvement with both drops, with no numerical difference between groups at 1 month. Neither drop had a clear effect on gland composite scores.

For optometrists, the 2 reviews point in the same direction: dry eye questionnaires are not reliable screening tools for Demodex blepharitis, and patients with MGD warrant direct evaluation of the lid margins and lashes.1,2 The Pucker trial suggests 1 month of either drop may improve tear stability without changing gland function, although the study was short and did not assess other MGD therapies.3

References
  1. Whitley W, Theriot P, Karpecki PM, et al. Assessment of dry eye questionnaires for Demodex blepharitis: evidence from a targeted literature review. Presented at: Academy 2026 Anaheim; September 30-October 1, 2026; Anaheim, CA.
  2. Shen Lee B, Koetting C, Li O, et al. Associations between Demodex infestation and meibomian gland structure and function: a systematic review. Presented at: Academy 2026 Anaheim; September 30-October 1, 2026; Anaheim, CA.
  3. Pucker AD, Wirta D, Lievens CW, et al. Assessing meibomian gland function in dry eye subjects treated with PFHO or Systane Pro. Presented at: Academy 2026 Anaheim; September 30-October 1, 2026; Anaheim, CA.

Related to this article